390 related articles for article (PubMed ID: 31642767)
1. STING Activation and its Application in Immuno-Oncology.
Lian Y; Duffy KJ; Yang J
Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
[TBL] [Abstract][Full Text] [Related]
2. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases.
Zhou S; Cheng F; Zhang Y; Su T; Zhu G
Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125
[TBL] [Abstract][Full Text] [Related]
3. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Iurescia S; Fioretti D; Rinaldi M
Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
[TBL] [Abstract][Full Text] [Related]
4. cGAS-STING, an important pathway in cancer immunotherapy.
Jiang M; Chen P; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; Ye L; He Y; Zhou C
J Hematol Oncol; 2020 Jun; 13(1):81. PubMed ID: 32571374
[TBL] [Abstract][Full Text] [Related]
5. Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.
Iurescia S; Fioretti D; Rinaldi M
Front Immunol; 2018; 9():711. PubMed ID: 29686682
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response.
Li T; Cheng H; Yuan H; Xu Q; Shu C; Zhang Y; Xu P; Tan J; Rui Y; Li P; Tan X
Sci Rep; 2016 Jan; 6():19049. PubMed ID: 26754564
[TBL] [Abstract][Full Text] [Related]
7. Insight into the dichotomous regulation of STING activation in immunotherapy.
Hu Z; Yang Y; Fang L; Zhou J; Zhang H
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
[TBL] [Abstract][Full Text] [Related]
8. cGAS-STING signaling in cancer immunity and immunotherapy.
Du H; Xu T; Cui M
Biomed Pharmacother; 2021 Jan; 133():110972. PubMed ID: 33254021
[TBL] [Abstract][Full Text] [Related]
9. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
10. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
[TBL] [Abstract][Full Text] [Related]
11. Assessing the cGAS-cGAMP-STING Activity of Cancer Cells.
Pépin G; Gantier MP
Methods Mol Biol; 2018; 1725():257-266. PubMed ID: 29322423
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
Corrales L; Gajewski TF
Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
[TBL] [Abstract][Full Text] [Related]
13. STING Signaling in Cancer Cells: Important or Not?
Sokolowska O; Nowis D
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):125-132. PubMed ID: 28748479
[TBL] [Abstract][Full Text] [Related]
14. Targeting STING for cancer immunotherapy: From mechanisms to translation.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
[TBL] [Abstract][Full Text] [Related]
15. Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists.
Pan X; Zhang W; Guo H; Wang L; Wu H; Ding L; Yang B
Biochem Pharmacol; 2023 Jul; 213():115596. PubMed ID: 37201875
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
[TBL] [Abstract][Full Text] [Related]
17. The cGas-Sting Signaling Pathway Is Required for the Innate Immune Response Against Ectromelia Virus.
Cheng WY; He XB; Jia HJ; Chen GH; Jin QW; Long ZL; Jing ZZ
Front Immunol; 2018; 9():1297. PubMed ID: 29963044
[TBL] [Abstract][Full Text] [Related]
18. cGAS-STING pathway in cancer biotherapy.
Wang Y; Luo J; Alu A; Han X; Wei Y; Wei X
Mol Cancer; 2020 Sep; 19(1):136. PubMed ID: 32887628
[TBL] [Abstract][Full Text] [Related]
19. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
[TBL] [Abstract][Full Text] [Related]
20. STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity.
Pei J; Zhang Y; Luo Q; Zheng W; Li W; Zeng X; Li Q; Quan J
Cancer Lett; 2019 May; 450():110-122. PubMed ID: 30790684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
